Featured Studies & Reports
Orphan Drug Development Strong 25 Years after the Orphan Drug Act
21 November, 2011 - A study recently reprinted by Nature Reviews Drug Discovery reported that since the passage of the U.S. Orphan Drug Act of 1983, 1,892 drugs have received orphan drug-designation and 326 have received marketing approval, representing more than 200 rare diseases. Since the mid-1990s there has been a nearly tripling in the annual number of orphan drug designations from 57 in 1996 to 165 in 2008.
Personalized Medicine Is Playing a Growing Role in Biopharmaceutical Development Pipelines
16 November, 2010 - A new report from the Tufts Center for the Study of Drug Development finds that biopharmaceutical companies are committed to researching and developing personalized medicines. The data show, for the first time, the extent to which companies are embracing this new research.
Major Advances in Cancer Medicines in 2010
8 November, 2010 - The American Society of Clinical Oncology (ASCO) has issued a new report, Clinical Cancer Advances 2010: ASCO’s Annual Report on Progress Against Cancer, outlining 53 of the most significant advances on the front lines of cancer research over the past year, including 12 major clinical advances in such key areas as personalized medicine and targeted therapies, new treatments and medications for specific diseases, reducing cancer recurrence, quality of life, and more.
Alzheimer’s Burden Will Balloon if New Treatments Are Not Found
15 May, 2010 - A new report from the Alzheimer’s Association examines the future impact of Alzheimer’s disease and the potential impact of new treatments. The study finds that on our current trajectory Alzheimer’s disease in adults over 65 will cost $1 trillion per year by 2050 and a total of $20 trillion in the next 40 years.
